Gonadotropin releasing hormone agonist treatment before hysteroscopic metroplasty

P. Vercellini, G. Ragni, A. Colombo, S. Oldani, S. Panazza, P. G. Crosignani

Research output: Contribution to journalArticlepeer-review


We performed hysteroscopic incision of uterine septum in 22 women with repeated abortion. The patients underwent surgery during the proliferative phase (group 1, 12 subjects) or 4 weeks after a subcutaneous goserelin (3.6 mg) depot injection (group 2, 10 subjects) to evaluate surgical and anatomic results in hypo-oestrogenic women. Metroplasty was performed with microscissors. After the operation the surgeon classified the intra-uterine operating conditions as unfavourable, usual or optimal. In group 1 the mean operating time was 19 min with a standard deviation (SD) of 5 min, compared with 13 min with a SD of 6 in group 2 (P = 0.02). The mean distension medium deficit was 620 ml with a SD of 175 in group 1 vs. 340 ml with a SD of 213 in group 2 (P = 0.003). One group 1 woman with partial uterine septum had a fundal perforation which was managed conservatively. The intra-uterine operating conditions were judged to be usual or optimal in 50% of cases in group 1 vs. 90% in group 2 (P = 0.04). At follow-up ultrasonography and hysteroscopy performed 2 months after surgery, a residual fundal notch ≥ 1 cm deep was detected and corrected in three patients in each group. In our series of hysteroscopic metroplasties, a single gonadotropin releasing hormone agonist depot injection improved the operating conditions, reducing the operating time and the distension fluid deficit. The anatomic results were comparable in the two study groups.

Original languageEnglish
Pages (from-to)153-157
Number of pages5
JournalGynaecological Endoscopy
Issue number3
Publication statusPublished - 1993


  • abortion
  • gonadotropin releasing hormone agonist
  • hysteroscopy
  • uterine malformations

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Obstetrics and Gynaecology


Dive into the research topics of 'Gonadotropin releasing hormone agonist treatment before hysteroscopic metroplasty'. Together they form a unique fingerprint.

Cite this